John Wilkerson and Daniel Payne , 2025-05-09 19:30:00
WASHINGTON — President Trump is widely expected to try to advance a “most-favored nation” policy next week in an effort to reduce U.S. drug prices — a move that is likely to significantly rattle the pharmaceutical industry, cheer his political base, and, possibly, leave open some very big questions.
The idea behind the policy, generally speaking, is simple: It would tie payments for drugs in the United States to prices paid by other high-income countries, many of which pay far less than Americans for their medications. It’s also not a new idea: The first Trump administration tried to set it in motion, only for its plans to be blocked.
But now, having learned the lessons from that defeat, and with a majority in the House and the Senate, the administration could face better odds.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
